juno therapy - Health Topics
July 7 (Reuters) - A trial of Juno Therapeutics Inc's genetically engineered cancer therapy, known as JCAR015, was put on hold by U.S. regulators after three leukemia patients died from side effects, ... According to data fromS&P Global Market Intelligence, shares of the clinical-stage biotech Juno Therapeutics (NASDAQ: JUNO) gained nearly 12% over the month of February without a discernible catalyst.
Understanding the Context
Becker's Hospital Review: FDA stops Juno’s cancer drug trials after 3 patients die The Food and Drug Administration halted Juno Therapeutics’ clinical trial for an experimental cancer drug following the death of three patients, according to Reuters. JCAR015 is a chimeric antigen ... What: Amid rising optimism for next-generation cancer therapies and ahead of fourth-quarter financial results that included a bullish drug development timeline, shares in Juno Therapeutics surged 29.2 ... Arizona Daily Star: Juno Therapeutics to Present at the Credit Suisse 24th Annual Healthcare Conference The presentation will feature a business overview and update by Hans Bishop, Juno’s Chief Executive Officer and President.
Image Gallery
Key Insights
Juno Therapeutics to Present at the Credit Suisse 24th Annual Healthcare Conference